

Roberta Sanfilippo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7039002/publications.pdf>

Version: 2024-02-01

49
papers

3,476
citations

218677

26
h-index

206112

48
g-index

49
all docs

49
docs citations

49
times ranked

3947
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. <i>Cancer Cell</i> , 2013, 23, 249-262.	16.8	721
2	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	10.7	416
3	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. <i>Cancer Research</i> , 2010, 70, 2235-2244.	0.9	251
4	Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 720-725.	1.5	199
5	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	1.2	180
6	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 1447-1454.	1.5	152
7	Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. <i>Annals of Oncology</i> , 2012, 23, 501-508.	1.2	130
8	Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. <i>Annals of Oncology</i> , 2009, 20, 1439-1444.	1.2	112
9	Mode of action of trabectedin in myxoid liposarcomas. <i>Oncogene</i> , 2014, 33, 5201-5210.	5.9	111
10	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	3.7	101
11	Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 1484-1490.	2.8	85
12	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	2.8	80
13	Health-related quality of life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (FORTC 62072). <i>Cancer</i> , 2015, 121, 2933-2941.	4.1	72
14	Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. <i>Gynecologic Oncology</i> , 2011, 123, 553-556.	1.4	68
15	<i>ERCC5</i> , <i>XPG</i> , <i>ERCC1</i> , and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. <i>Cancer</i> , 2011, 117, 3445-3456.	4.1	57
16	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP1 and TIMP2 and tumor thrombospondin1. <i>International Journal of Cancer</i> , 2015, 136, 721-729.	5.1	50
17	Trabectedin and Radiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , 2019, 9, 35-43.	7.1	49
18	High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 16.	2.3	44

#	ARTICLE	IF	CITATIONS
19	Trabectedin in advanced synovial sarcomas. <i>Anti-Cancer Drugs</i> , 2015, 26, 678-681.	1.4	44
20	Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. <i>British Journal of Surgery</i> , 2015, 102, 1079-1087.	0.3	43
21	Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. <i>Surgical Oncology</i> , 2016, 25, 125-131.	1.6	41
22	Trabectedin therapy for sarcomas. <i>Current Opinion in Oncology</i> , 2010, 22, 342-346.	2.4	40
23	Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma. <i>Clinical Cancer Research</i> , 2010, 16, 3581-3593.	7.0	40
24	Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1662-1670.	1.0	36
25	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. <i>Clinical Sarcoma Research</i> , 2013, 3, 16.	2.3	34
26	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	4.1	30
27	Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 848-857.	6.4	25
28	Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 4958-4967.	7.0	24
29	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società Italiana di Ginecologia Oncologica). <i>Journal of Gynecological Oncology</i> , 2017, 28, 1-11.	2.8	21
30	Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. <i>Clinical Sarcoma Research</i> , 2017, 7, 16.	2.3	20
31	BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. <i>British Journal of Cancer</i> , 2015, 112, 688-692.	6.4	18
32	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/differentiated liposarcomas. <i>Laboratory Investigation</i> , 2013, 93, 1232-1240.	3.7	17
33	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients: A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	3.7	17
34	Identification of a gene expression driven progression pathway in myxoid liposarcoma. <i>Oncotarget</i> , 2014, 5, 5965-5977.	1.8	16
35	Embryonal Rhabdomyosarcoma of the Uterine Cervix in Adults. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, e12-e17.	1.9	15
36	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	6.4	15

#	ARTICLE	IF	CITATIONS
37	Combination of PPAR β Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. <i>Clinical Cancer Research</i> , 2019, 25, 7565-7575.	7.0	15
38	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	3.7	15
39	Myxoid liposarcoma and the mammalian target of rapamycin pathway. <i>Current Opinion in Oncology</i> , 2013, 25, 379-383.	2.4	13
40	Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. <i>Cancers</i> , 2021, 13, 1453.	3.7	12
41	Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin downregulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 83.	8.6	11
42	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1723-1729.	1.0	10
43	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. <i>British Journal of Cancer</i> , 2019, 121, 464-473.	6.4	7
44	The intriguing patterns of tumor response to trabectedin. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 21-24.	2.4	6
45	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. <i>Sarcoma</i> , 2017, 2017, 1-5.	1.3	6
46	Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. <i>British Journal of Cancer</i> , 2012, 107, 612-616.	6.4	4
47	Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma. <i>Genomics</i> , 2021, 113, 3439-3448.	2.9	2
48	Uterine sarcomas: a multidisciplinary challenge. <i>European Journal of Cancer</i> , 2011, 47, S326-S327.	2.8	1
49	Medical Therapy in Retroperitoneal Sarcomas. <i>Updates in Surgery Series</i> , 2019, , 133-141.	0.1	0